Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The association between magnesium supplement use and a reduced risk of all-cause death or hospitalization was homogeneous, with no significant interactions, across subgroups of the IPTW-weighted cohort stratified by gender (p = 0.8413), BMI (p = 0.1875), serum vitamin D levels (p = 0.1469), prescribed multivitamin (p = 0.9108), diuretics (p = 0.1114), serum magnesium level (p = 0.7719), and left-ventricular ejection fraction (p = 0.1648).

Source: 3.2.3. Interactions and Stratified Subgroup Analyses. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Cohort study.

Cohort study

Examines exposures and outcomes over time within a defined group.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

This was a retrospective cohort study.

Source: Methods.

Regardless of whether participants were users or non-users, the follow-up began on the eligibility date.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Association Between Over-the-Counter Magnesium Supplement Use and Health Outcomes in Veterans with Newly Diagnosed Heart Failure

Cohort study · Nutrients · 2025

Original publication title

Association Between Over-the-Counter Magnesium Supplement Use and Health Outcomes in Veterans with Newly Diagnosed Heart Failure

Yan Cheng; Andrew R. Zullo; Ying Yin; Yijun Shao; Senait Tekle; Simin Liu; Qing Zeng-Treitler; Wen-Chih Wu

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Background: Individuals with heart failure (HF) are at increased risk of magnesium deficiency. Magnesium supplements are widely available and being used without clear evidence of efficacy in HF. Methods: We emulated a target trial to assess the association between magnesium supplements and adverse outcomes in U.S. veterans with newly diagnosed HF. Eligible patients were outpatients who received ambulatory care in the Veterans Health Administration between 1 January 2000 and 31 December 2020. Veterans with a hospitalization within 30 days prior to the eligible date, previous magnesium supplement or replacement use, or end-stage renal disease were ineligible for the trial.

Initial self-reported magnesium supplement use (measured at eligible date) was identified in medical records using natural language processing and then checked repeatedly to confirm continuous use. The outcome was all-cause hospitalization or death. Patients were followed for up to five years from the eligible date and were censored if they changed from the assigned treatment strategy or initiated prescribed magnesium replacement. We applied inverse probability treatment weighting and Cox’s regression to estimate hazard ratios (HRs), with sensitivity analyses in patients surviving ≥ 6 months and those with continuous documentation of magnesium supplement use.

Results: We enrolled 9900 magnesium supplement users and 9900 matched non-users. In the weighted cohort (mean age 72.6 years; 12.6% African American; 3.4% women; median follow-up 0.7 years), users had significantly better survival in both primary and sensitivity analyses (HR in primary analysis: 0.81 [0.77 to 0.86], p < 0.0001; HRs in sensitivity analyses: 0.91 [0.85 to 0.97], p = 0.0025 and 0.77 [0.72 to 0.82], p < 0.0001, respectively). Conclusions: magnesium supplement use was associated with a reduced risk of all-cause mortality or hospitalization among veterans with HF.

Authors’ abstract

Background: Individuals with heart failure (HF) are at increased risk of magnesium deficiency. Magnesium supplements are widely available and being used without clear evidence of efficacy in HF. Methods: We emulated a target trial to assess the association between magnesium supplements and adverse outcomes in U.S. veterans with newly diagnosed HF. Eligible patients were outpatients who received ambulatory care in the Veterans Health Administration between 1 January 2000 and 31 December 2020. Veterans with a hospitalization within 30 days prior to the eligible date, previous magnesium supplement or replacement use, or end-stage renal disease were ineligible for the trial.

Initial self-reported magnesium supplement use (measured at eligible date) was identified in medical records using natural language processing and then checked repeatedly to confirm continuous use. The outcome was all-cause hospitalization or death. Patients were followed for up to five years from the eligible date and were censored if they changed from the assigned treatment strategy or initiated prescribed magnesium replacement. We applied inverse probability treatment weighting and Cox’s regression to estimate hazard ratios (HRs), with sensitivity analyses in patients surviving ≥ 6 months and those with continuous documentation of magnesium supplement use.

Results: We enrolled 9900 magnesium supplement users and 9900 matched non-users. In the weighted cohort (mean age 72.6 years; 12.6% African American; 3.4% women; median follow-up 0.7 years), users had significantly better survival in both primary and sensitivity analyses (HR in primary analysis: 0.81 [0.77 to 0.86], p < 0.0001; HRs in sensitivity analyses: 0.91 [0.85 to 0.97], p = 0.0025 and 0.77 [0.72 to 0.82], p < 0.0001, respectively). Conclusions: magnesium supplement use was associated with a reduced risk of all-cause mortality or hospitalization among veterans with HF.

Publication and source details

Original title: Association Between Over-the-Counter Magnesium Supplement Use and Health Outcomes in Veterans with Newly Diagnosed Heart Failure

Yan Cheng; Andrew R. Zullo; Ying Yin; Yijun Shao; Senait Tekle; Simin Liu; Qing Zeng-Treitler; Wen-Chih Wu

Nutrients · 2025

* Correspondence: wen-chih.wu@va.gov; Tel.: +401-273-7100© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).National Health Lung and Blood Institute of the NIH Office of the Director5R01HL156518Office of Research and Development, Health Services Research and DevelopmentWashington DC VA Medical CenterThe research reported in this manuscript was supported by the National Health Lung and Blood Institute of the NIH Office of the Director under award number 5R01HL156518 and with resources from the Office of Research and Development, Health Services Research and Development, and the use of facilities at the Washington DC VA Medical Center.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T01:33:59.757066+00:00

DOI: 10.3390/nu17233687 · PMC12694171